You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 241 No. 16, April 20, 1979 TABLE OF CONTENTS
  JAMA
  •  Online Features
  ORIGINAL CONTRIBUTIONS
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Rebound Insomnia

A Potential Hazard Following Withdrawal of Certain Benzodiazepines

Anthony Kales, MD; Martin B. Scharf, PhD; Joyce D. Kales, MD; Constantin R. Soldatos, MD

JAMA. 1979;241(16):1692-1695.


Abstract

Five benzodiazepine drugs (diazepam, flunitrazepam, flurazepam hydrochloride, nitrazepam, and triazolam) were evaluated separately in 15 sleep laboratory studies. Rebound insomnia, a worsening of sleep compared with baseline, occurred following withdrawal of triazolam, nitrazepam, and flunitrazepam after they had been given in only single, nightly doses for short periods. The rebound insomnia was attributed to the short and intermediate half-lives of these drugs. Diazepam and flurazepam, which have longer half-lives, did not cause rebound insomnia on withdrawal. Rebound insomnia may play a role in the development of hypnotic drug dependence with shorter-acting benzodiazepine drugs.

(JAMA 241:1692-1695, 1979)



Author Affiliations

From the Sleep Research and Treatment Center and the Departments of Psychiatry (Drs A. Kales, Scharf, J. Kales, and Soldatos) and Pharmacology (Dr Scharf), Pennsylvania State University College of Medicine, Hershey.


Footnotes

Reprint requests to Department of Psychiatry, Sleep Research and Treatment Center, The Milton S. Hershey Medical Center, Hershey, PA 17033 (Dr A. Kales).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Zopiclone: Is it a pharmacologic agent for abuse?
Cimolai
cfp 2007;53:2124-2129.
ABSTRACT | FULL TEXT  

The safety and tolerability of zolpidem -- an update
Darcourt et al.
J Psychopharmacol 1999;13:81-93.
ABSTRACT  

Alprazolam in Panic Disorder and Agoraphobia: Results From a Multicenter Trial: III. Discontinuation Effects
Pecknold et al.
Arch Gen Psychiatry 1988;45:429-436.
ABSTRACT  

Management of Insomnia in Hospitalized Patients
BERLIN
ANN INTERN MED 1984;100:398-404.
ABSTRACT  

Long-term Diazepam Therapy and Clinical Outcome
Rickels et al.
JAMA 1983;250:767-771.
ABSTRACT  

Psychiatric Medicine: An Annotated Bibliography of Recent Literature
CASSEM et al.
ANN INTERN MED 1980;92:444-450.
 





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1979 American Medical Association. All Rights Reserved.